Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival. Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperatures and low water environments. It has distinctively large ears which dissipate heat and provide a very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo. Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo.

ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs.\nThe company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.

Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.

Edison is a world leader in the discovery and development of redox drugs. The company has obtained orphan designation in both the United States and Europe for its first drug candidate, EPI-743 . Vincerinone is now in phase 2 clinical development. It is being evaluated in multiple clinical indications where defects in the mitochondrial proteins and redox control have been well characterized.

Board of Trustees of Southern Illinois University, a subsidiary of Southern Illinois University, is an American company located in Carbondale, IL. The firm provides trust services.

Anida Pharma, Inc. is a biopharmaceutical company developing new therapies for orphan neurological indications with a focus on pediatric indications: retinopathy of prematurity (ROP), brain injury of the newborn (hypoxic-ischemic encephalopathy; HIE), and drug-induced hearing loss. Anida also has a program for the treatment of amyotrophic lateral sclerosis (ALS; Lou Gehrig disease).

Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR” technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified.

Dompe Farmaceutici SpA operates as a biopharmaceutical company. It develops pharmaceutical and biotechnological drugs. The firm provides updating and scientific assistance services to doctors of general medicine, paediatrics, pneumology, otology, orthopaedics, rheumatology, physiatrist, odontology, accident and emergency and first aid stations. The company was founded by Franco Domp�� in 1940 and is headquartered in Milan, Italy.

Altamira Therapeutics is dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus, and restore balance. Altamira Therapeutics is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo. They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.

Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo and tinnitus. The company was founded by Christian Chabbert, Gilles Desmadryl, Sylvain Bartolami and Sophie Gaboyard in 2009 and is headquartered in Montpellier, France.

BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA.

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The firm focuses on hearing disorders, including noise-induced hearing loss, residual hearing preservation or improved sound fidelity with cochlear implants, presbycusis or age-related hearing loss, tinnitus, a persistent ringing in the ears, and genetic hearing loss. It also offers drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. The company was founded in October 2015 and is headquartered in Boston, MA.

GemVax & KAEL Co., Ltd. engages in the production of chemical filters and gas scrubbers for semiconductors. It operates through the Pollution Removal and Bio businesses. Its products include carbon filter, coating resin, media, air refresher, mask, drugs and others. The company was founded on March 10, 1998 and is headquartered in Daejeon, South Korea.

At Elitac Wearables, we develop wearables from idea to commercially viable product – and any stage in-between – for the medical and safety domains. We specialise in integrating electronics and textiles, with a particular focus on haptic feedback technology and sensors. With our wearables, we want to help improve the daily lives of at least one million people before 2035. Development projects include: > BalanceBelt: Giving balance disorder patients back their freedom > NeuroShirt: Allowing surgeons to stay focused and operate more safely > SmartShoulder: Keeping service engineers safe, even in remote areas > Mission Navigation Belt: Helping soldiers stay safer by letting them concentrate fully on their surroundings while navigating Research projects include: > WEAFING: Developing an electro-active textile that will revolutionise wearables design | Funded by the European Union’s Horizon 2020 > GaitKeeper: Making it easier, faster, and safer for above knee amputees to learn how to walk with a prosthesis | Funded by Eurostars > 3DNav: Helping visually impaired people move around more safely | Funded by the Province of Utrecht